ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Antidepressants currently being prescribed by doctors don’t work for all patients, and when they do have an effect, they usually take weeks to kick in. To address these issues, researchers at the National Institute of Mental Health are testing a fast-acting compound from AstraZeneca, called AZD6765, on patients with major depressive disorder. Led by Carlos A. Zarate Jr., the scientists recently published the results of a Phase II clinical trial indicating that the drug has promise (Biol. Psychiatry, DOI: 10.1016/j.biopsych.2012.10.019). Typical FDA-approved antidepressants target nerve-cell receptors that bind neurotransmitters such as serotonin or dopamine. Like the hallucination-inducing street drug ketamine, AZD6765 targets and blocks a different receptor: the N-methyl-
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter